In this article, we will look at the 8 Most Promising Stocks to Buy According to Wall Street Analysts. Let’s look at where Iovance Biotherapeutics Inc. (IOVA) stands against other promising stocks according to Wall Street analysts.
With only a few days left until the 2024 presidential election, investors are preparing for potential volatility to shake the stock market. Uncertainty surrounds the winner of the November elections, whether Vice President Kamala Harris or former President Donald Trump will take. With around 62% of US adults invested in the stock markets, there are potentially particular ways for investors to manage and position their portfolios to reach profitability based on the election outcome, as there are differences in the Democratic and Republican economic policies.
However, despite this uncertainty, geopolitical tensions are already influencing market reactions. Tiffany McGhee, CEO and CIO at Pivotal Advisors, highlighted the potential macro events that could spark market volatility at the start of October. She was of the opinion that the ongoing conflict in the Middle East and the vice presidential debate are critical factors influencing market reactions. Bond prices experienced a decline earlier in the week but stabilized with investors looking for safety amidst the worsening geopolitical tensions. McGhee expects further short-term volatility as the elections approach due to these developments.
So, what should investors do to combat this volatility and ensure their profitability? McGhee prompted investors to reassess their portfolios, especially those with a heavy concentration in equities. With the S&P 500 up 20% year-to-date and sectors like consumer discretionary and technology performing on the better end of the spectrum, she suggests that this might be the time to take some profits off the table and think about reallocating these funds into different areas of the market to follow trends.
High Growth Sectors: Where Does Expert Opinion Point?
Market volatility and geopolitical trends are pushing investors to speculate about the most promising and high-growth sectors. On October 7, Keith Buchanan, GLOBALT Investments senior portfolio manager, appeared in an interview on Yahoo Finance to talk about what his expectations from the market are. With earning expectations revised from mid-single digits to mid-double digits, solid growth is expected as 2024 draws to a close. According to Buchanan, much of this growth is expected to come from artificial intelligence. In addition, expanding earnings growth beyond traditional growth in certain other sectors, like technology, is also anticipated to drive growth.
The energy and industrial sectors have experienced greater returns in 2024, capturing a significant portion of the market. Apart from value stocks and AI plays, Buchanan also adds that names in industrials, consumer discretionary, and financials are on the path to growth ahead for 2024. However, his advice to investors is prudent: to consider geopolitical events before diving head-first into investment decisions.
The stock market is thus exhibiting signs of its changing trends. Some of these are paving a profitable path for small caps. We discussed the potential of small-caps to rally in our article 7 Penny Stocks with Low PE Ratios. Here is an excerpt from it:
Larry Adam, chief investment officer at Raymond James, recently appeared in a CNBC interview and is of the opinion that the current market is precisely what a soft landing looks like. Talking about how lower interest rates are expected to benefit small caps, particularly the Russell 2000, Adam said that he believes the bull market will continue with the economy inching closer to a soft landing.
Small cap stocks get around 56% of their financing from the short end of the yield curve, which refers to the short-term interest rate on the yield curve. This typically represents the yields on bonds with shorter maturities, such as 2-year or 5-year Treasury notes. Large-cap companies, in contrast, get only 26% of their financing from these short ends of the curve. Therefore, Adam concludes that as the Fed continues to lower interest rates, small-cap companies will be better positioned to meet their financing needs.
He pointed out that the Fed is expected to cut rates twice in 2024 and another four times in 2025, painting a favorable picture for small caps. He iterated that the impact of the rate cuts has been positive for small caps, which have outperformed large caps. Taking this into a historical context, whenever the economy goes towards a soft landing, the circumstances help the small caps more significantly than the rest of the market.
Our Methodology
We used the Finviz screener to make a list of 25 mid cap stocks with a market cap of over $2 billion and selected the 30% above price column in the target price section. We picked the top 8 stocks with the highest analyst upside potential as of October 9, 2024. We have also added the hedge fund sentiment around the stocks, as of Q2 2024.
Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
8 Most Promising Stocks to Buy According to Wall Street Analysts
Iovance Biotherapeutics Inc. (NASDAQ:IOVA)
Analyst Upside Potential: 141.77%
Number of Hedge Funds: 33
Iovance Biotherapeutics (NASDAQ:IOVA) is a clinical-stage biopharmaceutical company that develops and delivers tumor-infiltrating lymphocyte (TIL) therapies for patients with solid tumor cancers. Its lead product candidate is Amtagvi (lifileucel), a tumor-derived autologous T-cell immunotherapy. The company is also developing next-generation therapies using TIL, including genetically modified TIL cell therapy.
The company has had a productive year following its first FDA approval and a successful start of the commercial launch of Amtagvi for patients with advanced melanoma in the US. Amtagvi is experiencing strong demand. Iovance Biotherapeutics’ (NASDAQ:IOVA) revenue reached $31.1 million in Q2, including recognized revenue for Proleukin and Amtagvi.
The initial quarter of product revenue from the company’s US launch shows early success in execution, broad patient access, and high awareness. With Amtagvi exhibiting a meaningful benefit for customers undergoing treatment in a commercial setting, the company expects continued launch momentum. It has a very engaged network of more than 50 currently authorized treatment centers (ATCs) with the infrastructure, training, and capabilities to treat patients with this drug.
Iovance Biotherapeutics (NASDAQ:IOVA) is on track to expand this network and will have at least 70 ATCs by the end of 2024. When achieved, this would represent the largest-ever initial ATC network for a cell therapy launch. The company has also initiated its community referral activities to boost additional demand for these ATCs. Strengthened by a strong logistics and scheduling collaboration between ATCs and the company, along with early success with reimbursement, the treatment is becoming faster for patients.
Iovance Biotherapeutics’ (NASDAQ:IOVA) commercial manufacturing capabilities are successfully delivering Amtagvi at an increasing pace, showing that the company is staffed to provide manufacturing slots and meet current and expected demand efficiently. It is scaling up its manufacturing according to growth projections, and has increased capacity and headcount every month since launch. The company ranks second on our list of the the 8 most promising stocks to buy among Wall Street analysts.
Artisan Small Cap Fund stated the following regarding Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) in its Q2 2024 investor letter:
“Among our top detractors for the quarter were Lattice Semiconductor and Iovance Biotherapeutics, Inc. (NASDAQ:IOVA). Iovance Biotherapeutics is a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor-infiltrating lymphocyte (TIL) cell therapies for cancer patients. The stock rallied significantly in Q1 after announcing that the FDA approved AMTAGVI™ (lifileucel) for advanced melanoma. Now that the scientific risk is behind the company, investor focus has shifted to the company’s commercial execution, and shares experienced weakness after the company reported earnings results. It announced the enrollment of more than 100 patients for therapy; however, this was not enough to alleviate investor concerns about patient attrition. In our view, there is no issue with the efficacy of its life-saving treatment. Headwinds have been caused by challenges in ramping production, which is understandable in the early days. We view these concerns as overblown and remain invested.”
Overall, IOVA ranks 2nd among the 8 most promising stocks to buy according to Wall Street analysts. While we acknowledge the potential of IOVA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than IOVA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. This article is originally published at Insider Monkey.
